Limits...
Relationship between oxidized low-density lipoprotein antibodies and obesity in different glycemic situations.

Babakr AT, Elsheikh OM, Almarzouki AA, Assiri AM, Abdalla BE, Zaki HY, Fatani SH, NourEldin EM - Diabetes Metab Syndr Obes (2014)

Bottom Line: Autoantibodies to oxidized low-density lipoprotein (oxLDL) are a heterogeneous group of antibodies that are controversially discussed to be either pathogenic or protective.The mean value for the control group was 73.5±27.5 U/L (P<0.001).The mean value for the control group was 20.4±10 U/L (P<0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.

ABSTRACT

Background: Autoantibodies to oxidized low-density lipoprotein (oxLDL) are a heterogeneous group of antibodies that are controversially discussed to be either pathogenic or protective. Biochemical and anthropometric measurements correlated with increased levels of these antibodies are also controversial, especially in conditions of impaired glucose tolerance and type 2 diabetes mellitus. The present study was conducted to evaluate levels of oxLDL antibodies and their correlation with obesity in different glycemic situations.

Methods: Two hundred and seventy-four adult males were classified into three subgroups: group 1 (n=125), comprising a control group of nondiabetic subjects; group 2 (n=77), comprising subjects with impaired glucose tolerance; and group 3 (n=72), comprising patients with type 2 diabetes mellitus. Body mass index was calculated, and measurement of oxLDL and oxLDL antibodies was performed.

Results: Higher mean concentrations of oxLDL were found in the type 2 diabetes mellitus and impaired glucose tolerance groups (143.5±21.9 U/L and 108.7±23.7 U/L, respectively). The mean value for the control group was 73.5±27.5 U/L (P<0.001). Higher mean concentrations of anti-oxLDL antibodies were observed in the type 2 diabetes mellitus and impaired glucose tolerance groups (55.7±17.8 U/L and 40.4±17.6 U/L, respectively). The mean value for the control group was 20.4±10 U/L (P<0.001). Levels of anti-oxLDL antibodies were found to be positively and significantly correlated with body mass index in the control group (r=0.46), impaired glucose tolerance (r=0.51), type 2 diabetes mellitus group (r=0.46), and in the whole study population (r=0.44; P<0.001).

Conclusion: Anti-oxLDL antibody levels were increased in subjects with type 2 diabetes mellitus and impaired glucose tolerance and were positively correlated with obesity and body mass index.

No MeSH data available.


Related in: MedlinePlus

Anti-oxidized LDL antibodies in the study groups.Abbreviations: LDL, low-density lipoprotein; DM, diabetes mellitus; IGT, impaired glucose tolerance.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4216034&req=5

f1-dmso-7-513: Anti-oxidized LDL antibodies in the study groups.Abbreviations: LDL, low-density lipoprotein; DM, diabetes mellitus; IGT, impaired glucose tolerance.

Mentions: Mean anti-oxLDL antibody levels were increased significantly in the IGT group (40.4±17.6 U/L, P<0.001) when compared with controls, and an even greater mean increase was found in the type 2 DM group (55.7±17.8 U/L, P<0.001). Elevated mean levels of these antibodies were found in obese controls (25.4±13.2 U/L) when compared with nonobese controls (17.7±6.4, P<0.001), as shown in Table 1. In the IGT group, mean anti-oxLDL antibody levels were also significantly (P<0.01) increased in obese (45.7±21 U/L) compared with nonobese (34.6±9.8 U/L) subjects. The difference in mean anti-oxLDL antibody levels between the obese and nonobese subgroups was not significant in the type 2 DM group (Figure 1).


Relationship between oxidized low-density lipoprotein antibodies and obesity in different glycemic situations.

Babakr AT, Elsheikh OM, Almarzouki AA, Assiri AM, Abdalla BE, Zaki HY, Fatani SH, NourEldin EM - Diabetes Metab Syndr Obes (2014)

Anti-oxidized LDL antibodies in the study groups.Abbreviations: LDL, low-density lipoprotein; DM, diabetes mellitus; IGT, impaired glucose tolerance.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4216034&req=5

f1-dmso-7-513: Anti-oxidized LDL antibodies in the study groups.Abbreviations: LDL, low-density lipoprotein; DM, diabetes mellitus; IGT, impaired glucose tolerance.
Mentions: Mean anti-oxLDL antibody levels were increased significantly in the IGT group (40.4±17.6 U/L, P<0.001) when compared with controls, and an even greater mean increase was found in the type 2 DM group (55.7±17.8 U/L, P<0.001). Elevated mean levels of these antibodies were found in obese controls (25.4±13.2 U/L) when compared with nonobese controls (17.7±6.4, P<0.001), as shown in Table 1. In the IGT group, mean anti-oxLDL antibody levels were also significantly (P<0.01) increased in obese (45.7±21 U/L) compared with nonobese (34.6±9.8 U/L) subjects. The difference in mean anti-oxLDL antibody levels between the obese and nonobese subgroups was not significant in the type 2 DM group (Figure 1).

Bottom Line: Autoantibodies to oxidized low-density lipoprotein (oxLDL) are a heterogeneous group of antibodies that are controversially discussed to be either pathogenic or protective.The mean value for the control group was 73.5±27.5 U/L (P<0.001).The mean value for the control group was 20.4±10 U/L (P<0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.

ABSTRACT

Background: Autoantibodies to oxidized low-density lipoprotein (oxLDL) are a heterogeneous group of antibodies that are controversially discussed to be either pathogenic or protective. Biochemical and anthropometric measurements correlated with increased levels of these antibodies are also controversial, especially in conditions of impaired glucose tolerance and type 2 diabetes mellitus. The present study was conducted to evaluate levels of oxLDL antibodies and their correlation with obesity in different glycemic situations.

Methods: Two hundred and seventy-four adult males were classified into three subgroups: group 1 (n=125), comprising a control group of nondiabetic subjects; group 2 (n=77), comprising subjects with impaired glucose tolerance; and group 3 (n=72), comprising patients with type 2 diabetes mellitus. Body mass index was calculated, and measurement of oxLDL and oxLDL antibodies was performed.

Results: Higher mean concentrations of oxLDL were found in the type 2 diabetes mellitus and impaired glucose tolerance groups (143.5±21.9 U/L and 108.7±23.7 U/L, respectively). The mean value for the control group was 73.5±27.5 U/L (P<0.001). Higher mean concentrations of anti-oxLDL antibodies were observed in the type 2 diabetes mellitus and impaired glucose tolerance groups (55.7±17.8 U/L and 40.4±17.6 U/L, respectively). The mean value for the control group was 20.4±10 U/L (P<0.001). Levels of anti-oxLDL antibodies were found to be positively and significantly correlated with body mass index in the control group (r=0.46), impaired glucose tolerance (r=0.51), type 2 diabetes mellitus group (r=0.46), and in the whole study population (r=0.44; P<0.001).

Conclusion: Anti-oxLDL antibody levels were increased in subjects with type 2 diabetes mellitus and impaired glucose tolerance and were positively correlated with obesity and body mass index.

No MeSH data available.


Related in: MedlinePlus